RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79

Bio-Techne (TECH) has an average buy rating and price target range of $65 to $95, according to analysts polled by Capital IQ. Price: 65.50, Change: +1.44, Percent Change: +2.25

MT NewswiresApr 29 21:39

Effective May 1, 2024, Bio-Techne Will Enter Into A Distribution Agreement With Thermo Fisher Scientific In Europe

Under this agreement, Thermo Fisher, through the European arm of its Fisher Scientific Channel, will distribute Bio-Techne's extensive portfolio of innovative products, including antibodies, proteins,

BenzingaApr 29 19:07

BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY

MINNEAPOLIS, April 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder (BM

PR NewswireApr 26 19:00

Global Market for Exosome Diagnostics, Therapeutics, and Research Tools (2021-2028) Featuring Bio-Techne, Exosomics, and System Biosciences - An Evaluation of New Commercial Opportunities and Emerging Trends

Yahoo FinanceApr 24 16:20

Getting In Cheap On Bio-Techne Corporation (NASDAQ:TECH) Is Unlikely

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may consider Bio-Techne Corporation (NASDAQ:TECH) as a stock to avoid entirely with its

Simply Wall StApr 19 19:08

Navigating 4 Analyst Ratings For Bio-Techne

In the preceding three months, 4 analysts have released ratings for Bio-Techne (NASDAQ:TECH), presenting a wide array of perspectives from bullish to bearish.Summarizing their recent assessments, the

BenzingaApr 19 00:01